Recently, β-Nicotinamide Mononucleotide (NMN) from Shenzhen Siyomicro Biotech Co., Ltd. successfully completed the U.S. New Dietary Ingredient (NDI) notification process following review by the FDA (NDIN No. 1495). This milestone marks an important step toward the compliant entry of this ingredient into the U.S. dietary supplement market. CIRS Group provided comprehensive support throughout the entire notification process.

The NDI notification is an important pre-market regulatory procedure for new dietary ingredients in the United States. Companies are required to submit scientific information to the FDA covering ingredient identity, manufacturing processes, specifications, proposed conditions of use, and supporting safety data. Following the statutory 75-day review period, if the FDA raises no objections, the ingredient may proceed toward market entry. Completing this process represents an important milestone for companies seeking to introduce ingredients into the U.S. market and build customer confidence.
NMN is a naturally occurring nucleotide in the human body and an important precursor in the biosynthesis of nicotinamide adenine dinucleotide (NAD⁺). NAD⁺ is involved in cellular energy metabolism and various physiological processes. As research into NMN and NAD⁺ metabolism continues to advance, NMN has attracted considerable attention as an ingredient in the nutrition, health, and healthy aging sectors. With the continued development of NMN research and applications, regulatory compliance in international markets has become an important part of companies’ global business strategies.
The successful completion of the U.S. NDI notification for NMN marks significant progress in Siyomicro’s international expansion and lays a solid foundation for strengthening partnerships with overseas customers and expanding into the U.S. dietary supplement market. Drawing on its extensive experience in global novel ingredient notifications, CIRS Group provided professional and efficient regulatory support, together with scientifically sound and comprehensive submission materials, the entire process took less than five months. This enabled Siyomicro to efficiently translate its R&D and industrialization achievements into a competitive advantage for international market expansion.
Looking ahead, CIRS Group will continue to monitor global regulatory developments concerning nutrition and health ingredients and support more synthetic biology companies in achieving regulatory compliance and expanding their presence in international markets.
About Siyomicro
Shenzhen Siyomicro Biotech Co., Ltd. is a globally leading innovator and manufacturer in synthetic biology. Driven by the integration of AI and biotechnology (AI + BT), the company has established three major R&D platforms. Siyomicro has independently developed a microbial resource database focused on microorganisms from extreme environments, establishing an integrated value chain spanning resource discovery, component development, and industrial commercialization, thereby strengthening its underlying technological capabilities.
With four independently operated R&D centers across Beijing and Shenzhen, Siyomicro is building a comprehensive synthetic biology ecosystem integrating industry, academia, research, and application. The company continuously strengthens its core competitiveness and has successfully brought multiple cutting-edge technology projects from the laboratory to commercialization. As one of China’s earliest synthetic biology companies, Siyomicro has developed a dual-driven growth model combining fundamental technologies with commercial innovation. It has successfully commercialized several bioactive ingredients, including ergothioneine, ectoine, and superoxide dismutase (SOD), with applications spanning functional skincare ingredients, functional food ingredients, flavors and fragrances, and other sectors.
What Can CIRS Do for You
Established in 2007, the CIRS Group is a leading product safety and regulatory consulting firm. CIRS has branch offices in the Republic of Ireland, South Korea, the United States, the United Kingdom, Japan, and China. CIRS Group utilizes its technical expertise, various resources, and international network to provide one-stop compliance services, from regulatory compliance, laboratory testing, and R&D to data services across multiple industries. This includes chemicals, cosmetics, food and food beverages, medical devices, agrochemical products, disinfectants, and consumer goods. It helps clients gain a competitive advantage by reducing business risks associated with regulatory affairs.
The vast majority of members in CIRS Food Business Division have over 10 years of professional experience in food compliance, with more than 80% holding Master’s or Doctoral degrees in food-related disciplines. The CIRS toxicology expert team consists of 24 Chinese Certified Toxicologists (DCST), 2 American Board Certified Toxicologists (DABT), and 1 European Registered Toxicologist (ERT). CIRS has provided one-stop food compliance services to over 1,000 domestic and international food and related enterprises. Leveraging its technical expertise, diverse resources, and global network, the CIRS Food Business Division offers global food compliance services, including but not limited to:
- Health food registration and filing in China;
- Application for “Three New Foods (new food additives, new food raw materials and new food-related products” in China;
- U.S. GRAS, NDI, and CAP notifications;
- EU Novel Food, food additives, and food enzymes applications; and
- Application for new feed ingredients and feed additives in China, the U.S., and the EU.
If you need any assistance or have any questions, please get in touch with us via service@cirs-group.com.

